$EDGE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in PDS Biotechnology Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in PDS Biotechnology Corp. Get notifications about new insider transactions in PDS Biotechnology Corp for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 25 2017 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Buy | M | 2.04 | 25,000 | 51,000 | 595,602 | 570.6 K to 595.6 K (+4.38 %) |
| Dec 02 2016 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 11.60 | 7,500 | 87,000 | 252,979 | 260.5 K to 253 K (-2.88 %) |
| Nov 02 2016 | EDGE | Edge Therapeutics, ... | BRENNAN DANIEL | Chief Operating Off ... | Option Exercise | A | 10.09 | 150,000 | 1,513,500 | 150,000 | |
| Oct 04 2016 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.25 | 7,500 | 76,844 | 260,479 | 268 K to 260.5 K (-2.80 %) |
| Aug 09 2016 | EDGE | Edge Therapeutics, ... | MIDDLEKAUFF W BRADFORD | Senior VP, GC and S ... | Buy | P | 9.43 | 143 | 1,348 | 10,000 | 9.9 K to 10 K (+1.45 %) |
| Aug 09 2016 | EDGE | Edge Therapeutics, ... | MIDDLEKAUFF W BRADFORD | Senior VP, GC and S ... | Buy | P | 9.48 | 9,857 | 93,444 | 9,857 | 0 to 9.9 K |
| Aug 02 2016 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 9.54 | 7,500 | 71,582 | 267,979 | 275.5 K to 268 K (-2.72 %) |
| Aug 02 2016 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 9.54 | 7,500 | 71,582 | 267,979 | 275.5 K to 268 K (-2.72 %) |
| Jun 23 2016 | EDGE | Edge Therapeutics, ... | Ratcliffe Liam | Director | Option Exercise | A | 9.34 | 30,000 | 280,200 | 30,000 | |
| Jun 23 2016 | EDGE | Edge Therapeutics, ... | HEALY JAMES | Director | Option Exercise | A | 9.34 | 15,000 | 140,100 | 15,000 | |
| Jun 23 2016 | EDGE | Edge Therapeutics, ... | BLECH ISAAC | Director | Option Exercise | A | 9.34 | 15,000 | 140,100 | 15,000 | |
| Jun 23 2016 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Option Exercise | A | 9.34 | 15,000 | 140,100 | 15,000 | |
| Jun 23 2016 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Option Exercise | A | 9.34 | 15,000 | 140,100 | 15,000 | |
| Jun 23 2016 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | A | 9.34 | 15,000 | 140,100 | 15,000 | |
| Jun 23 2016 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | A | 9.34 | 15,000 | 140,100 | 15,000 | |
| Jun 23 2016 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Option Exercise | A | 9.34 | 30,000 | 280,200 | 30,000 | |
| Jun 23 2016 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Option Exercise | A | 9.34 | 30,000 | 280,200 | 30,000 | |
| Jun 23 2016 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Option Exercise | A | 9.34 | 15,000 | 140,100 | 15,000 | |
| Mar 15 2016 | EDGE | Edge Therapeutics, ... | HEALY JAMES | Director | Buy | P | 7.30 | 541,343 | 3,951,641 | 2,852,711 | 2.3 M to 2.9 M (+23.42 %) |
| Mar 15 2016 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Buy | P | 7.63 | 180 | 1,373 | 3,000 | 2.8 K to 3 K (+6.38 %) |
| Mar 15 2016 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Buy | P | 7.63 | 500 | 3,814 | 2,820 | 2.3 K to 2.8 K (+21.55 %) |
| Mar 15 2016 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Buy | P | 7.64 | 600 | 4,583 | 2,320 | 1.7 K to 2.3 K (+34.88 %) |
| Mar 15 2016 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Buy | P | 7.64 | 1,107 | 8,456 | 1,720 | 613 to 1.7 K (+180.59 %) |
| Mar 15 2016 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Buy | P | 7.64 | 500 | 3,820 | 613 | 113 to 613 (+442.48 %) |
| Mar 15 2016 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Buy | P | 7.63 | 13 | 99 | 113 | 100 to 113 (+13.00 %) |
| Mar 15 2016 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Buy | P | 7.58 | 100 | 758 | 100 | 0 to 100 |
| Mar 02 2016 | EDGE | Edge Therapeutics, ... | Faleck Herbert J | Chief Medical Offic ... | Option Exercise | A | 7.24 | 25,000 | 181,000 | 25,000 | |
| Feb 18 2016 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Accounting & ... | Option Exercise | A | 6.99 | 35,000 | 244,650 | 35,000 | |
| Feb 18 2016 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Option Exercise | A | 6.99 | 85,000 | 594,150 | 85,000 | |
| Feb 18 2016 | EDGE | Edge Therapeutics, ... | Vaish Renu | V.P., Global Reg. A ... | Option Exercise | A | 6.99 | 30,500 | 213,195 | 30,500 | |
| Feb 18 2016 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Option Exercise | A | 6.99 | 230,000 | 1,607,700 | 230,000 | |
| Feb 18 2016 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Option Exercise | A | 6.99 | 50,000 | 349,500 | 50,000 | |
| Feb 18 2016 | EDGE | Edge Therapeutics, ... | Yaman Alpaslan | V.P., Technical Ops ... | Option Exercise | A | 6.99 | 35,000 | 244,650 | 35,000 | |
| Feb 18 2016 | EDGE | Edge Therapeutics, ... | MIDDLEKAUFF W BRADFORD | Senior VP, GC and S ... | Option Exercise | A | 6.99 | 35,000 | 244,650 | 35,000 | |
| Feb 18 2016 | EDGE | Edge Therapeutics, ... | Faleck Herbert J | Chief Medical Offic ... | Option Exercise | A | 6.99 | 110,000 | 768,900 | 110,000 | |
| Nov 18 2015 | EDGE | Edge Therapeutics, ... | MIDDLEKAUFF W BRADFORD | Senior VP, GC and S ... | Option Exercise | A | 14.92 | 80,000 | 1,193,600 | 80,000 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Option Exercise | C | 0.00 | 1,080,000 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Option Exercise | C | 0.00 | 20,000 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Option Exercise | C | 0.00 | 20,000 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Option Exercise | C | 0.00 | 40,000 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Option Exercise | C | 0.00 | 224,000 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Option Exercise | C | 0.00 | 220,000 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Buy | C | 0.00 | 789,420 | 0 | 789,420 | 0 to 789.4 K |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Buy | C | 0.00 | 14,619 | 0 | 14,619 | 0 to 14.6 K |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Buy | C | 0.00 | 14,619 | 0 | 14,619 | 0 to 14.6 K |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Buy | C | 0.00 | 29,238 | 0 | 29,238 | 0 to 29.2 K |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Buy | C | 0.00 | 163,731 | 0 | 324,541 | 160.8 K to 324.5 K (+101.82 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Buy | C | 0.00 | 160,810 | 0 | 160,810 | 0 to 160.8 K |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Option Exercise | C | 0.00 | 144,086 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Option Exercise | C | 0.00 | 65,809 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Option Exercise | C | 0.00 | 114,285 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Option Exercise | C | 0.00 | 480,000 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Buy | J | 6.17 | 12,735 | 78,575 | 645,545 | 632.8 K to 645.5 K (+2.01 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Buy | P | 11.00 | 45,000 | 495,000 | 632,810 | 587.8 K to 632.8 K (+7.66 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Buy | C | 0.00 | 105,319 | 0 | 587,810 | 482.5 K to 587.8 K (+21.83 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Buy | C | 0.00 | 48,103 | 0 | 482,491 | 434.4 K to 482.5 K (+11.07 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Buy | C | 0.00 | 83,536 | 0 | 434,388 | 350.9 K to 434.4 K (+23.81 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Buy | C | 0.00 | 350,852 | 0 | 350,852 | 0 to 350.9 K |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Option Exercise | C | 0.00 | 16,774 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Buy | J | 8.60 | 364 | 3,130 | 19,625 | 19.3 K to 19.6 K (+1.89 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Buy | P | 11.00 | 7,000 | 77,000 | 19,261 | 12.3 K to 19.3 K (+57.09 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Buy | C | 0.00 | 12,261 | 0 | 12,261 | 0 to 12.3 K |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | C | 0.00 | 14,409 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | C | 0.00 | 32,258 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Buy | J | 7.91 | 1,549 | 12,253 | 38,661 | 37.1 K to 38.7 K (+4.17 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Buy | P | 11.00 | 3,000 | 33,000 | 37,112 | 34.1 K to 37.1 K (+8.79 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Buy | C | 0.00 | 10,533 | 0 | 34,112 | 23.6 K to 34.1 K (+44.67 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Buy | C | 0.00 | 23,579 | 0 | 23,579 | 0 to 23.6 K |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | HEALY JAMES | Director | Option Exercise | C | 0.00 | 2,473,118 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | HEALY JAMES | Director | Buy | J | 8.60 | 53,665 | 461,519 | 2,311,368 | 2.3 M to 2.3 M (+2.38 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | HEALY JAMES | Director | Buy | P | 11.00 | 450,000 | 4,950,000 | 2,257,703 | 1.8 M to 2.3 M (+24.89 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | HEALY JAMES | Director | Buy | C | 0.00 | 1,807,703 | 0 | 1,807,703 | 0 to 1.8 M |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Option Exercise | C | 0.00 | 5,373 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Option Exercise | C | 0.00 | 25,000 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Buy | J | 7.90 | 194 | 1,533 | 570,602 | 570.4 K to 570.6 K (+0.03 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Buy | C | 0.00 | 3,928 | 0 | 570,408 | 566.5 K to 570.4 K (+0.69 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Buy | C | 0.00 | 18,274 | 0 | 566,480 | 548.2 K to 566.5 K (+3.33 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Option Exercise | C | 0.00 | 29,032 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Option Exercise | C | 0.00 | 21,506 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Option Exercise | C | 0.00 | 32,956 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Option Exercise | C | 0.00 | 6,494 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Option Exercise | C | 0.00 | 14,286 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Buy | J | 7.75 | 1,651 | 12,795 | 83,592 | 81.9 K to 83.6 K (+2.01 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Buy | P | 11.00 | 45,000 | 495,000 | 81,941 | 36.9 K to 81.9 K (+121.82 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Buy | C | 0.00 | 21,221 | 0 | 36,941 | 15.7 K to 36.9 K (+134.99 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Buy | C | 0.00 | 15,720 | 0 | 15,720 | 0 to 15.7 K |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Buy | J | 6.79 | 2,377 | 16,140 | 41,656 | 39.3 K to 41.7 K (+6.05 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Buy | C | 0.00 | 24,089 | 0 | 39,279 | 15.2 K to 39.3 K (+158.58 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Buy | C | 0.00 | 4,747 | 0 | 15,190 | 10.4 K to 15.2 K (+45.46 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Buy | C | 0.00 | 10,443 | 0 | 10,443 | 0 to 10.4 K |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Hove Anders D | Director | Option Exercise | C | 0.00 | 2,150,538 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Hove Anders D | Director | Buy | J | 8.60 | 46,665 | 401,319 | 2,068,582 | 2 M to 2.1 M (+2.31 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Hove Anders D | Director | Buy | P | 11.00 | 450,000 | 4,950,000 | 2,021,917 | 1.6 M to 2 M (+28.63 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Hove Anders D | Director | Buy | C | 0.00 | 1,571,917 | 0 | 1,571,917 | 0 to 1.6 M |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | Chief Executive Off ... | Option Exercise | C | 0.00 | 3,655 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | Chief Executive Off ... | Buy | J | 8.60 | 80 | 688 | 550,958 | 550.9 K to 551 K (+0.01 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | Chief Executive Off ... | Buy | C | 0.00 | 2,672 | 0 | 550,878 | 548.2 K to 550.9 K (+0.49 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Acct. & Op., ... | Option Exercise | C | 0.00 | 7,530 | 0 | 0 | |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Acct. & Op., ... | Buy | J | 7.24 | 357 | 2,585 | 6,861 | 6.5 K to 6.9 K (+5.49 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Acct. & Op., ... | Buy | P | 11.00 | 100 | 1,100 | 6,504 | 6.4 K to 6.5 K (+1.56 %) |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Acct. & Op., ... | Buy | C | 0.00 | 5,504 | 0 | 5,504 | 0 to 5.5 K |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Vaish Renu | V.P., Global Reg. A ... | Buy | P | 11.00 | 350 | 3,850 | 350 | 0 to 350 |
| Oct 08 2015 | EDGE | Edge Therapeutics, ... | Faleck Herbert J | Chief Medical Offic ... | Buy | P | 11.00 | 500 | 5,500 | 500 | 0 to 500 |